Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in relapsed/refractory metastatic germ cell cancer (phase II, single-arm)
2009-014383-18Phase 2Completed
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in germ cell tumor (GCT) and testicular cancer, sponsored by Medizinische Hochschule Hannover. Primary endpoints: Percentage of patients progression-free at 12 weeks and Percentage of patients progression-free. Started Jul 2010; status: completed.
02
Drugs
everolimus
03
Conditions
germ cell tumor (GCT)testicular cancer
Beyond the preview
Go deeper on 2009-014383-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014383-18.